Diagnostic Value of Whole-Body MRI Compared to FDG-PET-CT for Rectal Cancer Preoperative Staging, Before and After Neoadjuvant Treatment
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Rectal Cancer
- Sponsor
- University of Lausanne Hospitals
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- Evaluate the diagnostic accuracy of whole-body MRI for the staging of rectal cancer before and after neoadjuvant treatment
- Last Updated
- 13 years ago
Overview
Brief Summary
The purpose of this study is to determine whether whole-body MRI (WB-MRI) accuracy is superior to FDG-PET-CT considered as the gold-standard for the staging of distant lesions of rectal cancer.
Detailed Description
Rectal cancer is the second cause of mortality after lung cancer in industrialized countries and represent 28% of colorectal carcinomas. Despite major improvements in diagnosis and treatment made those last years,mortality and morbidity remains high, because of high prevalence of metastasis and local recurrence. A accurate initial staging is of paramount importance for an appropriate treatment (neoadjuvant chemiotherapy and radiotherapy, surgery). Actually, there is no international consensus concerning imaging for the staging of rectal cancer and modalities used are variable from one center to another. WB-MRI represented a attractive and promising technique for the staging of rectal cancer, free of ionizing radiation .
Investigators
Milena Cerny
Dr. Milena Cerny
University of Lausanne Hospitals
Eligibility Criteria
Inclusion Criteria
- •rectal cancer T3 N+ or T3 or T4
Exclusion Criteria
- •renal failure
- •allergy to iodinated contrast medium
- •contraindication to MRI
Outcomes
Primary Outcomes
Evaluate the diagnostic accuracy of whole-body MRI for the staging of rectal cancer before and after neoadjuvant treatment
Time Frame: baseline and 1 week before surgery
We will compare for each body region the findings of the whole-body MRI to the FDG-PET-CT considered as the gold-standard and measure sensibility/specificity and diagnostic accuracy of the whole-body MRI for distant lesions of rectal cancer.
Secondary Outcomes
- Tumoral regression after neoadjuvant treatment(baseline and six weeks after the end of the neoadjuvant treatment)